x

Posted 16 May, 2023

INTUITIVE SURGICAL INC appointed new CEO

CEO Change detected for ticker Nasdaq:ISRG in a 8-K filed on 16 May, 2023.


  On May 15, 2023, the Board of Directors of Intuitive Surgical, Inc. (the "Company" or "Intuitive") promoted David J. Rosa to the role of President of the Company, effective May 16, 2023. In connection with Mr. Rosa's promotion, Gary S. Guthart, Ph.D., will cease to hold the title of President and will continue to serve as the Company's Chief Executive Officer and as a member of its Board of Directors.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of INTUITIVE SURGICAL INC
Health Care/Life Sciences • Medical Equipment/Supplies
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.
Market Cap
$141B
View Company Details
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On May 15, 2023, the Board of Directors of Intuitive Surgical, Inc. (the "Company" or "Intuitive") promoted David J. Rosa to the role of President of the Company, effective May 16, 2023. In connection with Mr. Rosa's promotion, Gary S. Guthart, Ph.D., will cease to hold the title of President and will continue to serve as the Company's Chief Executive Officer and as a member of its Board of Directors. Mr. Rosa will continue to report directly to Dr. Guthart.

David J. Rosa, age 55, joined Intuitive in March 1996 and has held leadership positions across the organization in commercial, engineering, clinical development, marketing, and product development. In April 2011, Mr. Rosa was promoted to the position of Senior Vice President, Emerging Procedures & Technology, and transitioned to the position of Senior Vice President, Scientific Affairs. In August 2014, Mr. Rosa was promoted to the position of Executive Vice President and Chief Scientific Officer. In June 2015, Mr. Rosa was appointed as Executive Vice President and Chief Commercial Officer. In January 2019, Mr. Rosa took on additional responsibility as Executive Vice President and Chief Business Officer. In January 2022, Mr. Rosa transitioned to Chief Strategy and Growth Officer. Mr. Rosa also currently serves on the Board of Directors of Kardium Inc. Mr. Rosa graduated magna cum laude with a B.S. in Mechanical Engineering from California Polytechnic University at San Luis Obispo. He also holds a Master of Science in Mechanical Engineering from Stanford University.

In connection with Mr. Rosa's promotion to President, his annual base salary was increased from $652,468 to $700,000, and his targeted bonus opportunity under the Company's Corporate Incentive Program for the fiscal year 2023 performance period was increased from 100% to 120% of his base salary. In addition, Mr. Rosa will receive, pursuant to the Company's Amended and Restated 2010 Incentive Award Plan, grants of (i) an option to purchase shares of the Company's common stock with a value of $1,500,000 ("Target Stock Option Value"), (ii) restricted stock units ("RSUs") with a value of $1,500,000 ("Target RSU Value") and (iii) performance stock units ("PSUs") with a value of $2,000,000 ("Target PSU Value"), whose metrics are consistent with the 2023 annual grant of PSUs. The number of shares underlying the stock option will be determined by dividing the Target Stock Option Value by one-third of the 60 trading-day average closing price of the Company's common stock, as reported by Nasdaq, through the last trading day of the month prior to the grant date (the "60 Trading-Day Average"). The number of RSUs and target number of PSUs will be determined by dividing each of the Target RSU Value and Target PSU Value by the 60 Trading-Day Average. The shares subject to the option will vest 25% on the first anniversary of the grant and 1/48 per month thereafter, and the shares subject to the RSUs will vest 25% annually over a four-year period. The shares subject to the PSUs will vest as to 0-125% of the target number of PSUs after a three-year period based on the achievement of certain performance objectives.

There are no transactions in which Mr. Rosa had or will have a direct or indirect material interest that are required to be reported under Item 404(a) of Regulation S-K.